m+Medelevator.RU
← Поиск публикаций
[Zhonghua yan ke za zhi] Chinese journal of ophthalmology · 2021

[Evidence-based guidelines for diagnosis and treatment of demyelinating optic neuritis in China(2021)].

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Neuro-ophthalmology Group of Ophthalmology Branch of Chinese Medical Association, Evidence-based Medicine Center of Lanzhou University/World Health Organization Collaborating Centre for Guideline Implementation and Knowledge Translation

Аннотация

Demyelinating optic neuritis (DON) is an inflammatory demyelinating disease of the central nervous system, which can lead to visual loss in young adults as a major factor. The key points concerned by neuro-ophthalmologists are to reduce the rate of recurrence and improve the prognosis in the course of diagnosis and treatment of DON. Companied with the deep research of diagnostic markers, different classifications and therapies, and evidence-based medicine, there are more and more clinical evidences for the development and standardization of evidence-based guidelines for diagnosis and treatment. According to the routine procedures, the expert steering committee, the guideline development group, the external review expert group and the working group were established. The clinical concerns were collected directly from neuro-ophthalmologists, ophthalmologists of other subspecialties and neurologists. The guideline development group comprehensively searched and systematically evaluated the relevant research evidence at home and abroad, analyzed the preferences and values of patients, and organized the expert consensus meeting. Sixteen recommendations for the diagnosis and treatment of DON were formulated, including classification and diagnosis, therapies in acute and chronic phases, and the follow-up management, which has important guiding significance for the improvement of clinical treatment and reduction of the recurrence rate. (Chin J Ophthalmol, 2021, 57:171-186).

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты